All these results were obtained by double suppression of ASCT2 (SLC1A5) and GLUL in B16F10 and CAFs cells with reprogramming of TME metabolism, which further eliminated tumor ECM and increased nanodrug penetration. This evidence concerns the gene SLC1A5 and neoplasm.